Get access

Single-Dose and Multiple-Dose Pharmacokinetics and Safety of Telbivudine After Oral Administration in Healthy Chinese Subjects


Address for correspondence: Xiao-Jian Zhou, PhD, Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139; e-mail:


The pharmacokinetics of telbivudine, an L-nucleoside with potent activity against hepatitis B virus, was assessed in 42 healthy Chinese volunteers. Subjects were assigned to receive a single oral dose of 200, 400, or 800 mg telbivudine or repeat doses of 600 mg/d. Telbivudine was absorbed rapidly and exhibited dose-related plasma exposure. After reaching maximum concentration (Cmax) at a median time of 2.0 to 2.5 hours, plasma disposition of the drug was biphasic with a mean terminal half-life ranging from 39.4 to 49.1 hours. Telbivudine accumulated slightly after repeat doses, and steady state was reached after 5 to 6 consecutive doses of 600 mg/d. The mean steady-state Cmax and area under the plasma concentration–time curve over the dosing interval of telbivudine 600 mg were 3.7 μg/mL and 26.1 μg·h/mL, respectively. Cumulative urinary excretion of telbivudine over 32 hours represented 24.4% of the administered dose, with a mean renal clearance of 6.6 L/h. Telbivudine was well tolerated in the studied dose range in healthy Chinese subjects, with no pattern of dose-related clinical or laboratory adverse events.